---
title: "Cribriform on Follow-up Biopsy Predicts Active Surveillance Failure in MRI-Era Prostate Cancer"
id: "medrxiv-21-cribriform-status-at-follow-up-biopsy-is-critical-for-predicting-prostate"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-21-cribriform-status-at-follow-up-biopsy-is-critical-for-predicting-prostate"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.19.26365918v1?rss=1"
published_at: "2026-10-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Cribriform on Follow-up Biopsy Predicts Active Surveillance Failure in MRI-Era Prostate Cancer
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-21-cribriform-status-at-follow-up-biopsy-is-critical-for-predicting-prostate
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.19.26365918v1?rss=1)
- **Published At:** 2026-10-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Retrospective, MRI-driven active surveillance cohort included 619 men across two academic centres (UK and USA) spanning 2012–2024. The analysis used cumulative incidence and multivariable Fine-Gray competing-risk models. - Median follow-up was 6.4 years. Over that period 39 of 619 men (6%) met the study’s composite primary outcome defined as AS failure (disease-specific death, metastasis, progression to grade group ≥4, or post-treatment biochemical recurrence). - **Cribriform ≥GG2** was present on follow-up biopsy in 82/619 (13%) versus 24/619 (4%) at baseline. The authors reported roughly three-fold higher cribriform prevalence at follow-up, which they attribute to baseline sampling error. - Newly detected cribriform tumours were reported only within **MRI-visible** lesions. Detection on follow-up conferred a markedly higher short-term event rate: three-year AS failure after the final biopsy was 31% with cribriform ≥GG2, versus 0–2% in men with stable or non-cribriform disease. - On multivariable Fine-Gray analysis among re-biopsied men, cribriform ≥GG2 was the sole independent predictor of AS failure (subdistribution hazard ratio 30; 95% CI 5.2–167; P<0.001). No MRI progression category independently predicted failure. - Among 595 men who were cribriform-negative at baseline, six-year AS failure after a second biopsy was 34% if cribriform ≥GG2 was detected versus 7% if still cribriform-negative. - The investigators conclude that cribriform status at follow-up biopsy stratifies risk beyond MRI progression, and suggest that early repeat biopsy in patients with MRI-visible disease may improve risk classification. - The study was retrospective, conducted at two academic centres, and the authors note data are available on request. The preprint has not undergone peer review.
## Clinical Analysis & Structured Key Points
Cribriform Status at Follow-up Biopsy Is Critical for Predicting Prostate Cancer Active Surveillance Failure in the MRI Era: a Transatlantic Cohort Study | medRxiv Skip to main content Cribriform Status at Follow-up Biopsy Is Critical for Predicting Prostate Cancer Active Surveillance Failure in the MRI Era: a Transatlantic Cohort Study Nikita Sushentsev , George Xu , Irene G Li , Son Do , Jasmine Liu , Max Kim , Christof Kastner , Sean Fernando , Anders M Dale , Anne Y Warren , Anders M Dale , Michael Liss , Tristan Barrett , Tyler M Seibert doi: https://doi.org/10.64898/2026.10.19.26365918 Nikita Sushentsev 1 University of Cambridge; Find this author on Google Scholar Find this author on PubMed Search for this author on this site George Xu 2 University of California San Diego; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Irene G Li 2 University of California San Diego; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Son Do 2 University of California San Diego; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jasmine Liu 2 University of California San Diego; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Max Kim 2 University of California San Diego; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Christof Kastner 3 Cambridge University Hospitals NHS Foundation Trust Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sean Fernando 1 University of Cambridge; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Anders M Dale 2 University of California San Diego; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Anne Y Warren 3 Cambridge University Hospitals NHS Foundation Trust Find this author on Google Scholar Find this author on PubMed Search for this author on this site Anders M Dale 2 University of California San Diego; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Michael Liss 2 University of California San Diego; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tristan Barrett 1 University of Cambridge; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tyler M Seibert 2 University of California San Diego; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: tseibert{at}health.ucsd.edu Abstract Info/History Metrics Data/Code Preview PDF Abstract Purpose To assess whether follow-up MRI, biopsy status, and timing of cribriform disease detection predict active surveillance (AS) failure in a contemporary transatlantic cohort. Materials and Methods. Retrospective MRI-driven AS cohort of 619 men at two academic centers (UK/USA), 2012-2024. Primary outcome: AS failure (disease-specific mortality, metastasis, grade group [GG] ≥4 progression, or post-treatment biochemical recurrence). Key exposures: final MRI and biopsy status, timing of cribriform ≥GG2 detection. Cumulative incidence was derived; independent predictors used multivariable Fine-Gray models. Results. Over median follow-up of 6.4 years, 39/619 men (6%) experienced AS failure. Cribriform ≥GG2 was detected in 82/619 (13%) on follow-up biopsy versus 24/619 (4%) at baseline, comparably in baseline GG1 (10%) and non-cribriform GG2 (9%), and only in MRI-visible tumors. Three-year AS failure after final biopsy was 31% in men with cribriform ≥GG2 versus 0-2% with stable or non-cribriform disease; 44% of failures had stable MRI. On Fine-Gray analysis, cribriform ≥GG2 was the only independent predictor of AS failure in re-biopsied men (SHR 30; 95% CI 5.2-167; P<0.001); no type of MRI progression category was independently predictive. Among 595 men cribriform-negative at baseline, 6-year AS failure after a second biopsy was 34% if cribriform ≥GG2 was detected versus 7% if still cribriform-negative. Conclusions. Cribriform status at follow-up biopsy independently predicts AS failure, whereas MRI progression does not. The three-fold higher cribriform prevalence at follow-up likely reflects baseline sampling error. Because newly detected cribriform tumours were exclusively MRI-visible, early repeat biopsy of patients with MRI-visible disease may considerably improve risk stratification. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Institutional review boards of the Cambridge University Hospitals (CUH/18/3592) and University of California San Diego (191878) gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors. Funder Information Declared Prostate Cancer Foundation, https://ror.org/01npwtv09 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Back to top Previous Next Posted October 21, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Cribriform Status at Follow-up Biopsy Is Critical for Predicting Prostate Cancer Active Surveillance Failure in the MRI Era: a Transatlantic Cohort Study Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Cribriform Status at Follow-up Biopsy Is Critical for Predicting Prostate Cancer Active Surveillance Failure in the MRI Era: a Transatlantic Cohort Study Nikita Sushentsev , George Xu , Irene G Li , Son Do , Jasmine Liu , Max Kim , Christof Kastner , Sean Fernando , Anders M Dale , Anne Y Warren , Anders M Dale , Michael Liss , Tristan Barrett , Tyler M Seibert medRxiv 2026.10.19.26365918; doi: https://doi.org/10.64898/2026.10.19.26365918 Share This Article: Copy Citation Tools Cribriform Status at Follow-up Biopsy Is Critical for Predicting Prostate Cancer Active Surveillance Failure in the MRI Era: a Transatlantic Cohort Study Nikita Sushentsev , George Xu , Irene G Li , Son Do , Jasmine Liu , Max Kim , Christof Kastner , Sean Fernando , Anders M Dale , Anne Y Warren , Anders M Dale , Michael Liss , Tristan Barrett , Tyler M Seibert medRxiv 2026.10.19.26365918; doi: https://doi.org/10.64898/2026.10.19.26365918 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (631) Allergy and Immunology (914) Anesthesia (343) Cardiovascular Medicine (4936) Dentistry and Oral Medicine (490) Dermatology (425) Emergency Medicine (668) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1664) Epidemiology (16148) Forensic Medicine (35) Gastroenterology (1232) Genetic and Genomic Medicine (7198) Geriatric Medicine (747) Health Economics (1087) Health Informatics (5212) Health Policy (1454) Health Systems and Quality Improvement (1811) Hematology (597) HIV/AIDS (1369) Infectious Diseases (except HIV/AIDS) (16416) Intensive Care and Critical Care Medicine (1191) Medical Education (689) Medical Ethics (156) Nephrology (738) Neurology (7479) Nursing (374) Nutrition (1112) Obstetrics and Gynecology (1275) Occupational and Environmental Health (1028) Oncology (3704) Ophthalmology (1078) Orthopedics (401) Otolaryngology (462) Pain Medicine (489) Palliative Medicine (142) Pathology (715) Pediatrics (1841) Pharmacology and Therapeutics (747) Primary Care Research (780) Psychiatry and Clinical Psychology (6059) Public and Global Health (9903) Radiology and Imaging (2495) Rehabilitation Medicine and Physical Therapy (1497) Respiratory Medicine (1262) Rheumatology (655) Sexual and Reproductive Health (793) Sports Medicine (593) Surgery (794) Toxicology (109) Transplantation (315) Urology (302)
## Related Clinical Research

- [Tailored Treatment Approaches for Breast Cancer in Older Women](https://medichelpline.com/clinical-feed/stat-news-5-breast-cancer-can-behave-differently-in-older-women-this-physician-is-making.md)
- [Using Skin UV Mutagenesis to Reveal Genetic Cancer Predisposition: EPHB2 Identified](https://medichelpline.com/clinical-feed/medrxiv-7-leveraging-skin-mutagenesis-to-uncover-genetic-cancer-susceptibilities.md)
- [Genome-wide genetic dataset generated for the Australian 45 and Up Study](https://medichelpline.com/clinical-feed/medrxiv-17-a-genome-wide-genetic-data-resource-for-the-45-and-up-study.md)
- [Hormonal Management in Older Transgender and Gender Diverse Adults: Case-Based Considerations](https://medichelpline.com/clinical-feed/pubmed-42274359.md) (DOI: 10.1210/clinem/dgag231)
- [Healthy lifestyle and pan-cancer risk: UK Biobank prospective analysis](https://medichelpline.com/clinical-feed/british-journal-of-cancer-2-healthy-lifestyle-and-cancer-risk-a-pan-cancer-analysis-in-the-uk-biobank.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.